These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 35790864)

  • 1. A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma.
    Zhang G; Sun J; Zhang X
    Sci Rep; 2022 Jul; 12(1):11325. PubMed ID: 35790864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs.
    Wei M; Lu L; Luo Z; Ma J; Wang J
    BMC Gastroenterol; 2024 Apr; 24(1):142. PubMed ID: 38654165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer.
    Xu Q; Liu T; Wang J
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 12. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
    Zhang H; Ning Z; Wang B; Liu Y; Tao B; Zhang G; Liu H; Wang C
    Dis Markers; 2023; 2023():7219794. PubMed ID: 36741910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
    Xu Q; Wang Y; Huang W
    Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
    Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
    Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma.
    Chen S; Liu P; Zhao L; Han P; Liu J; Yang H; Li J
    Front Immunol; 2022; 13():954653. PubMed ID: 36189204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
    Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
    Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNAs in ferroptosis and cuproptosis impact on prognosis and treatment in hepatocellular carcinoma.
    Wang K; Yang C; Xie J; Zhang X; Wei T; Yan Z
    Clin Exp Med; 2024 Jun; 24(1):135. PubMed ID: 38907744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
    Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
    Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.